Actively Recruiting
qEEG Brain Signature of Depression & Neuromodulation-induced Recovery
Led by Sunnybrook Health Sciences Centre · Updated on 2025-03-03
100
Participants Needed
2
Research Sites
155 weeks
Total Duration
On this page
Sponsors
S
Sunnybrook Health Sciences Centre
Lead Sponsor
M
Mitacs
Collaborating Sponsor
AI-Summary
What this Trial Is About
This study aims to explore how repetitive transcranial magnetic stimulation (rTMS), a treatment for depression, affects brain function. Depression disrupts the brain's complex network or regions that regulate cognition, emotion, and behavior. rTMS targets these disruptions to restore network function. To measure these effects, researchers will use dry quantitative EEG (qEEG), a new technology that records brain electrical activity quickly (15 minutes compared to 1 hour for traditional EEG) without the need for gel or lengthy electrode setups. This study will evaluate a novel qEEG activity developed by iMediSync (Republic of South Korea) in patients treated with neuromodulation for depression before, during, and up to 12 months after treatment to see if changes in brain activity to identify patterns associated with symptomatic improvement and relapse risk. Findings could help personalize depression treatments by predicting patient outcomes and optimizing care.
CONDITIONS
Official Title
qEEG Brain Signature of Depression & Neuromodulation-induced Recovery
Who Can Participate
Eligibility Criteria
You may qualify if you...
- Diagnosis of depression based on DSM 5.0 criteria
- Currently receiving rTMS treatment for depression at the HCN
- Physically healthy
- Age between 18 and 80 years, inclusive
- Able to provide informed consent and follow the study protocol
- Communication ability not a reason for exclusion unless caused by other exclusion criteria
You will not qualify if you...
- Moderate or severe substance use disorder based on DSM 5.0 and clinical assessment
- Mild or major comorbid medical conditions like neurological diseases, uncontrolled hypertension or diabetes, or malignancy
- Major comorbid psychiatric disorder such as schizophrenia or bipolar disorder, or psychosis at enrollment
- History of seizure disorder
- Pregnancy
AI-Screening
AI-Powered Screening
Complete this quick 3-step screening to check your eligibility
Trial Site Locations
Total: 2 locations
1
Sunnybrook Health Sciences Centre
North York, Ontario, Canada, M4N 3M5
Not Yet Recruiting
2
Sunnybrook Health Sciences Centre
Toronto, Ontario, Canada, M4N 3M5
Actively Recruiting
Research Team
S
Sean M Nestor, M.D.
CONTACT
C
Chris B Pople, MSc
CONTACT
How is the study designed?
Study Type
INTERVENTIONAL
Masking
NONE
Allocation
RANDOMIZED
Model
SINGLE_GROUP
Primary Purpose
TREATMENT
Number of Arms
2
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here